Stockscreener 앱 받기
0.20
48.15%
0.065
시간 외 거래:
.20
전일 마감가:
$0.135
열려 있는:
$0.1919
하루 거래량:
536.20M
Relative Volume:
61.81
시가총액:
$1.33M
수익:
-
순이익/손실:
$-22.70M
주가수익비율:
-0.0457
EPS:
-4.38
순현금흐름:
$-26.07M
1주 성능:
-55.56%
1개월 성능:
-59.99%
6개월 성능:
-74.55%
1년 성능:
-90.52%
1일 변동 폭
$0.156
$0.3168
1주일 범위
$0.121
$0.49
52주 변동 폭
$0.121
$3.4899
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
명칭
Hepion Pharmaceuticals Inc
전화
732-902-4000
주소
399 THORNALL STREET, EDISON
HEPA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HEPA
Hepion Pharmaceuticals Inc
|
0.20 | 1.33M | 0 | -22.70M | -26.07M | -4.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.73 | 110.00B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.64 | 74.82B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
652.19 | 38.43B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.54 | 34.12B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.12 | 27.56B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-07-20 | 재개 | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc 주식(HEPA)의 최신 뉴스
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales - Benzinga
Hepion Pharmaceuticals launches public offering for proceeds of up to $9M; shares tumble - MSN
Stock market today: Star Fashion Culture Holdings jumped by 680.92% while Hepion Pharmaceuticals saw increase of 147.54% in early trading - Business Upturn
Hepion Pharmaceuticals launches $9 million stock offering - Investing.com India
Hepion Pharmaceuticals announces $9M public offering - TipRanks
Hepion Pharmaceuticals Announces $9.0 Million Public Offering - The Manila Times
Hepion Pharmaceuticals Announces $9M Public Offering with Dual Warrant Structure - StockTitan
Hepion Pharmaceuticals faces potential Nasdaq delisting - Investing.com
HEPA stock touches 52-week low at $0.43 amid market challenges - Investing.com
HEPA stock touches 52-week low at $0.43 amid market challenges By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Quotes, Forecast and News Summary - Benzinga
HEPA stock touches 52-week low at $0.46 amid market challenges - Investing.com Canada
Comparing Novo Nordisk A/S (NYSE:NVO) and Hepion Pharmaceuticals (NASDAQ:HEPA) - Defense World
HEPA stock touches 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
HEPAHepion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Hepion Pharmaceuticals Terminates Merger with Pharma Two B - TipRanks
HEPA stock touches 52-week low at $0.49 amid market challenges - Investing.com
Hepion Pharmaceuticals cancels merger and stockholder meeting By Investing.com - Investing.com Canada
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - The Manila Times
Hepion Pharmaceuticals Terminates Strategic Merger with Pharma Two BMajor Deal Cancelled - StockTitan
Oligonucleotide Therapy Market Key Players AnalysisBPCI - openPR
Pharma Two B Announces Poster Presentation on P2B001 at the - GlobeNewswire
Hepion Pharmaceuticals (NASDAQ:HEPA) Shares Down 4.1% – Here’s What Happened - Defense World
Hepion urges shareholder support for Pharma Two B merger - Investing.com India
Hepion urges shareholder support for Pharma Two B merger By Investing.com - Investing.com Canada
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - The Manila Times
Hepion Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com Nigeria
Hepion Pharmaceuticals faces Nasdaq delisting risk - Investing.com India
HEPA (Hepion Pharmaceuticals) 3-Year EPS without NRI Growth Rate : 35.30% (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Accounts Receivable : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Long-Term Debt & Capital Leas - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Analysis of ARMISTICE CAPITAL, LLC's Recent Transaction in Hepio - GuruFocus.com
Hepion Pharmaceuticals Inc (CTVRP) Quarterly 10-Q Report - Quartzy
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger - The Manila Times
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce - GlobeNewswire
Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67% - MSN
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Will Hepion's AMBITION Be Fulfilled? - RTTNews
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Hypha Labs, Inc. Releases Investor Presentation - AccessWire
Does Hyliion Holdings Corporation (NYSE: HYLN) Still Need To Convince Analysts? - Stocks Register
FluoRok raises US$ 9.8million for safety and sustainability of fluorochemical production - Indian Chemical News
FLO stock rated an Underperform by Exane BNP Paribas - Knox Daily
Barrow Hanley Mewhinney & Strauss LLC Purchases Shares of 898,419 Helios Technologies, Inc. (NASDAQ:HLIO) - MarketBeat
Hancock Whitney Corp Buys 10,920 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat
FluoRok Raises £7.7M in Funding - FinSMEs
Oxford's FluoRok secures €9.2M from BGF and others - Silicon Canals
Hepion Pharmaceuticals Inc (HEPA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
10.10%
자본화:
|
볼륨(24시간):